Daraxonrasib Nearly Doubles Survival in 500-Patient Pancreatic Cancer Trial, Drawing 42-Second ASCO Ovation
Updated
Updated · Vox.com · Jun 6
Daraxonrasib Nearly Doubles Survival in 500-Patient Pancreatic Cancer Trial, Drawing 42-Second ASCO Ovation
3 articles · Updated · Vox.com · Jun 6
Summary
Daraxonrasib nearly doubled median overall survival in a 500-patient trial for previously treated advanced pancreatic cancer, prompting a 42-second standing ovation when Harvard oncologist Brian Wolpin presented the data at ASCO in Chicago.
ASCO leaders and outside oncologists called the result a “grand slam” and a “game changer” because pancreatic cancer remains one of the deadliest, most treatment-resistant cancers, killing more than 50,000 Americans a year.
The breakthrough landed amid broader signs of progress in oncology: the U.S. cancer death rate has fallen 34% since its 1991 peak, while five-year survival across all cancers reached 70% for patients diagnosed in 2015-2021.
ASCO also highlighted newer fronts including immunotherapy, personalized mRNA vaccines and early detection, though many findings remain preliminary and the newest cancer drugs carry steep costs.
That momentum faces a policy risk as 2025 cuts and freezes to NIH and NSF funding disrupted hundreds of clinical trials, threatening the federally backed research pipeline behind many recent advances.
A new drug doubles survival for a fatal cancer. Is this the turning point for all untreatable diseases?
New cancer drugs offer miraculous hope, but what is the human cost when a cure is unaffordable?
As scientists celebrate cancer breakthroughs, are funding cuts quietly threatening the next wave of life-saving cures?
Daraxonrasib Sets New Standard: 60% Reduction in Mortality for Metastatic Pancreatic Cancer in Phase III Trial
Overview
At the ASCO 2026 annual meeting, Daraxonrasib made history by unveiling groundbreaking Phase III RASolute 302 trial results, showing a significant overall survival benefit for patients with metastatic pancreatic cancer. As a novel multiselective RAS(ON) inhibitor, Daraxonrasib is designed to target activated KRAS signaling across a broad range of RAS variants, setting it apart from earlier KRAS inhibitors. Its ability to inhibit KRAS activity regardless of the specific variant and demonstrate efficacy in both RAS-mutant and wild-type tumors marks a major advance, offering new hope for a disease with few effective treatments.